Navigation Links
FASgen Announces New Discovery for Treatment of Stroke
Date:12/20/2007

BALTIMORE, Dec. 20 /PRNewswire/ -- FASgen is pleased to announce the recent publication of important results from research into a potential treatment for stroke using one of FASgen's proprietary compounds, C75. The Company is a leader in the research in the field of FASi (fatty acid synthase inhibition). One area of that research has been for the treatment of metabolic disease disorders, including obesity. As the regulation of appetite is centered in the hypothalamus in the brain, research was undertaken to evaluate the safety of the Company's compounds in the brain. An unexpected and significant discovery resulted when the studies demonstrated not only that the compounds were non-toxic in the brain, but also they had the positive effect of providing significant neuroprotection in the case of ischemic stroke. In the stroke models tested, the Company's compound C-75 reduced AMPK levels and resulted in neuroprotection by reduced stroke damage, even when administered poststroke. These remarkable findings were recently published in the article, "Neuroprotective Effects of Adenosine Monophosphate-Activated Protein Kinase Inhibition and Gene Deletion in Stroke," McCullough et al, Stroke 2007, 38; 2992-2999 (December 11, 2007).

About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.

The Company has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer; additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders; and, an addi
'/>"/>

SOURCE FASgen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... Harvard Pilgrim achieves CORE Phase II Testing Certification with ... that are now required in X12 Version 5010BELLEVUE, Wash., ... it will, together with its partners CAQH and Harvard ... from the CORE Phase II Certification testing including elements ...
... Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs ... (FDA) has finalized its discussions of questions related to liraglutide, ... questions related to the risk profile of liraglutide. , ... A majority of Advisory Committee members supported that ...
Other Medicine Technology:Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 2Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 3Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 4Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 5Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes 2Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes 3
(Date:5/23/2012)... second edition of Law and the American Health Care ... 2012. Building on its 1997 predecessor, the second edition ... intersection of law and the U.S. health care system. ... a time of unprecedented change in how health care ... of study, the book focuses on how a dramatically ...
(Date:5/23/2012)... of the same kind, thereby triggering skeletal and cardiac ... from the RUB Heart and Diabetes Center NRW in ... an interdisciplinary research project with colleagues from the universities ... Journal of Biological Chemistry . , One ... stabilizing filaments inside of the cells. Different mutations in ...
(Date:5/23/2012)... FRANCISCO The number of viral infections during infancy ... to a new study from researchers in the Netherlands. ... later in childhood, this association was due in part ... in infancy, particularly rhinovirus, are thought to be a ... unclear whether this association is due to the viruses ...
(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...
(Date:5/22/2012)... MAYWOOD, Ill. -- Children born with cleft lip, ... medical challenges beyond appearance. , Patients can face ... well as social and psychological challenges, Laura Swibel ... colleagues write in the June 2012 issue of ... "The management of patients with craniofacial syndromes is ...
Breaking Medicine News(10 mins):Health News:Landmark textbook on health care and the US legal system released 2Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Cleft lip/palate cause much more than cosmetic problems 2
... SPRINGS, Fla., June 2 Boca Pharmacal, Inc.,announced ... has granted,final approval for the Company,s Abbreviated New ... Pamlab,s Palgic(R) 4mg Tablet (Carbinoxamine,Maleate 4 mg Tablet). ... Carbinoxamine Maleate 4mg Tablet is indicated to ...
... Featuring Live Performances by The Who and Tribute,Bands Pearl Jam, Foo ... July 17 at 9:00pm* from the Pauley Pavilion ... first time ever, fans will,have the opportunity to see some of ... on sale for the network,s third annual "VH1 Rock,Honors" event paying ...
... performance determines ranking as second fastest growing ... ... Dynamics Company,Ltd.) (TSX: IDL), the global leader in the rapidly growing ... Canada,s,sixth fastest growing company in the 20th annual PROFIT 100 by ...
... first-line drug for type 2 diabetes, may be effective ... with early stage breast cancer who took the drug ... for further research of the drug as a potential ... Texas M. D. Anderson Cancer Center. , The retrospective ...
... June 2 The following event,announcement was released ... Epidemiology:, WHAT:, Association for Professionals in ... and International Meeting, WHEN:, Sunday - ... Convention Center, Denver, CO, 700 14th Street ...
... June 2 The New Jersey,Hospital Association this ... counsel, NJHA,s president-designee Betsy Ryan announced., Jacobs, ... Ali,who has been named NJHA,s vice president of ... will provide direction on all legal matters,to NJHA ...
Other Medicine News:Health News:'VH1 Rock Honors: The Who' Tickets Go on Sale Sunday, June 8 with Proceeds to Benefit the Efforts of Multiple Charities 2Health News:'VH1 Rock Honors: The Who' Tickets Go on Sale Sunday, June 8 with Proceeds to Benefit the Efforts of Multiple Charities 3Health News:'VH1 Rock Honors: The Who' Tickets Go on Sale Sunday, June 8 with Proceeds to Benefit the Efforts of Multiple Charities 4Health News:'VH1 Rock Honors: The Who' Tickets Go on Sale Sunday, June 8 with Proceeds to Benefit the Efforts of Multiple Charities 5Health News:IDC ranked no. 6 of Canada's 100 fastest growing companies by PROFIT Magazine 2Health News:IDC ranked no. 6 of Canada's 100 fastest growing companies by PROFIT Magazine 3Health News:Metformin increases pathologic complete response rates in breast cancer patients with diabetes 2
... have been designed to optimize the accuracy ... our tip products is widely recognized by ... has been extended over the years and ... and special tips including filter tips, certified ...
... Tips offer a safe alternative to using ... for applications such as PCR(a), pipetting radioactive ... Tips are excellent for tissue culture, gel ... Tips prevent aerosol contaminants and liquids from ...
... 3000 combines a powerful motor with a ... nozzle rotates to three positions for maximum ... the nozzle release button on the top ... nozzle position. The wide-angle position is ideal ...
... Peroxidase stain is the gold standard ... better agreement with your technologists manual ... efficiency. ,True RBC morphology advances cell ... allows for the differentiation of various ...
Medicine Products: